Lataa...
Trastuzumab: updated mechanisms of action and resistance in breast cancer
HER2-postitive breast cancer has the second-poorest prognosis among breast cancer subtypes. One of the most effective targeted therapies for patients with HER2-positive breast cancer is trastuzumab-based. However, primary or acquired resistance to trastuzumab has been a major obstacle in the clinica...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2012-06-01
|
| Sarja: | Frontiers in Oncology |
| Aiheet: | |
| Linkit: | http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00062/full |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|